Skip to main content
Top
Published in: Hepatology International 1/2022

01-02-2022 | Stroke | Original Article

Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke

Authors: Takahisa Mori, Kazuhiro Yoshioka, Yuhei Tanno

Published in: Hepatology International | Issue 1/2022

Login to get access

Abstract

Background/purpose of the study

If non-alcoholic fatty liver disease (NAFLD) frequency is very high in stroke patients, NAFLD may be a risk factor for stroke and identifying factors of NAFLD presence may lead to stroke prevention. This retrospective study aimed to investigate whether NAFLD frequency was very high and identify factors associated with NAFLD presence at acute stroke admission.

Methods

We included stroke patients aged 40 − 79 years who (1) were admitted from 2016 to 2019, within 24 h of onset; (2) underwent abdominal ultrasonography; and (3) underwent blood examination of biomarkers. We evaluated the frequency and significant factors of NAFLD presence.

Results

Among 1672 stroke patients, 676 patients met our inclusion criteria, and 267 patients (39.5%) had NAFLD. Compared to patients without NAFLD, patients with NAFLD were young; had high anthropometric values; high blood pressure; low aspartate aminotransferase/alanine aminotransferase ratio (AST/ALT) ratio; high levels of liver enzymes, serum albumin, HbA1c, and serum lipids; low-density lipoprotein; high serum level of some fatty acids; and high fatty acid% of palmitic acid (PA) and dihomo-gamma-linolenic acid (DGLA). After excluding variables with multicollinearity, independent NAFLD-presence factors were high body mass index (BMI), low AST/ALT ratio, high serum albumin level, high PA%, and high DGLA level.

Conclusions

The frequency of NAFLD was high in our patient group. Significant NAFLD-presence factors were high BMI, low AST/ALT ratio, high serum albumin level, high PA%, and high DGLA level. A further study is warranted to determine the effects of the NAFLD-presence factors on stroke onset or prevention.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005;143:722–728CrossRef Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005;143:722–728CrossRef
2.
go back to reference Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579–1584CrossRef Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579–1584CrossRef
4.
go back to reference Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, Meng X, Wu S, Wang Y. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke 2021;52:103–110CrossRef Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, Meng X, Wu S, Wang Y. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke 2021;52:103–110CrossRef
6.
go back to reference Yokoyama M, Watanabe T, Otaki Y, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Konta T, Shibata Y, Daimon M, Ueno Y, Kato T, Kayama T, Kubota I. Association of the aspartate aminotransferase to alanine aminotransferase ratio with bnp level and cardiovascular mortality in the general population: the Yamagata Study 10-year follow-up. Dis Markers 2016;2016:4857917. https://doi.org/10.1155/2016/4857917CrossRefPubMedPubMedCentral Yokoyama M, Watanabe T, Otaki Y, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Konta T, Shibata Y, Daimon M, Ueno Y, Kato T, Kayama T, Kubota I. Association of the aspartate aminotransferase to alanine aminotransferase ratio with bnp level and cardiovascular mortality in the general population: the Yamagata Study 10-year follow-up. Dis Markers 2016;2016:4857917. https://​doi.​org/​10.​1155/​2016/​4857917CrossRefPubMedPubMedCentral
8.
go back to reference Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, Liang C, Li J. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget 2017;9:2752–2760CrossRef Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, Liang C, Li J. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget 2017;9:2752–2760CrossRef
9.
go back to reference Alkagiet S, Papagiannis A, Tziomalos K. Associations between non-alcoholic fatty liver disease and ischemic stroke. World J Hepatol 2018;10:474–478CrossRef Alkagiet S, Papagiannis A, Tziomalos K. Associations between non-alcoholic fatty liver disease and ischemic stroke. World J Hepatol 2018;10:474–478CrossRef
10.
go back to reference Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K, Itoh Y. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol 2015;50:95–108CrossRef Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K, Itoh Y. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol 2015;50:95–108CrossRef
11.
go back to reference Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between non-alcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol 2013;5:621–626CrossRef Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between non-alcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol 2013;5:621–626CrossRef
12.
go back to reference Abdeldyem SM, Goda T, Khodeir SA, Abou Saif S, Abd-Elsalam S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol 2017;11:915–919CrossRef Abdeldyem SM, Goda T, Khodeir SA, Abou Saif S, Abd-Elsalam S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol 2017;11:915–919CrossRef
16.
go back to reference Yaemsiri S, Sen S, Tinker LF, Robinson WR, Evans RW, Rosamond W, Wasserthiel-Smoller S, He K. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013;2013(44):2710–2717CrossRef Yaemsiri S, Sen S, Tinker LF, Robinson WR, Evans RW, Rosamond W, Wasserthiel-Smoller S, He K. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013;2013(44):2710–2717CrossRef
19.
go back to reference Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082–1090CrossRef Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082–1090CrossRef
20.
go back to reference Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol 2015;50:364–377CrossRef Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol 2015;50:364–377CrossRef
23.
go back to reference Tsurutani Y, Inoue K, Sugisawa C, Saito J, Omura M, Nishikawa T. Increased serum dihomo-gamma-linolenic acid levels are associated with obesity, body fat accumulation, and insulin resistance in Japanese patients with type 2 diabetes. Intern Med 2018;57:2929–2935CrossRef Tsurutani Y, Inoue K, Sugisawa C, Saito J, Omura M, Nishikawa T. Increased serum dihomo-gamma-linolenic acid levels are associated with obesity, body fat accumulation, and insulin resistance in Japanese patients with type 2 diabetes. Intern Med 2018;57:2929–2935CrossRef
25.
go back to reference Umeda-Sawada R, Fujiwara Y, Ushiyama I, Sagawa S, Morimitsu Y, Kawashima H, Ono Y, Kiso Y, Matsumoto A, Seyama Y. Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. Biosci Biotechnol Biochem 2006;70:2121–2130CrossRef Umeda-Sawada R, Fujiwara Y, Ushiyama I, Sagawa S, Morimitsu Y, Kawashima H, Ono Y, Kiso Y, Matsumoto A, Seyama Y. Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. Biosci Biotechnol Biochem 2006;70:2121–2130CrossRef
27.
go back to reference Saito A, Imai S, Htun NC, Okada E, Yoshita K, Yoshiike N, Takimoto H. The trends in total energy, macronutrients and sodium intake among Japanese: findings from the 1995–2016 National Health and Nutrition Survey. Br J Nutr 2018;120:424–434CrossRef Saito A, Imai S, Htun NC, Okada E, Yoshita K, Yoshiike N, Takimoto H. The trends in total energy, macronutrients and sodium intake among Japanese: findings from the 1995–2016 National Health and Nutrition Survey. Br J Nutr 2018;120:424–434CrossRef
28.
go back to reference Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke 2013;44:278–286CrossRef Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke 2013;44:278–286CrossRef
29.
go back to reference Shijo Y, Maruyama C, Nakamura E, Nakano R, Shima M, Mae A, Okabe Y, Park S, Kameyama N, Hirai S. Japan diet intake changes serum phospholipid fatty acid compositions in middle-aged men: a pilot study. J Atheroscler Thromb 2019;26:3–13CrossRef Shijo Y, Maruyama C, Nakamura E, Nakano R, Shima M, Mae A, Okabe Y, Park S, Kameyama N, Hirai S. Japan diet intake changes serum phospholipid fatty acid compositions in middle-aged men: a pilot study. J Atheroscler Thromb 2019;26:3–13CrossRef
30.
go back to reference Maruyama C, Nakano R, Shima M, Mae A, Shijo Y, Nakamura E, Okabe Y, Park S, Kameyama N, Hirai S, Nakanishi M, Uchida K, Nishiyama H. Effects of a Japan diet intake program on metabolic parameters in middle-aged men. J Atheroscler Thromb 2017;24:393–401CrossRef Maruyama C, Nakano R, Shima M, Mae A, Shijo Y, Nakamura E, Okabe Y, Park S, Kameyama N, Hirai S, Nakanishi M, Uchida K, Nishiyama H. Effects of a Japan diet intake program on metabolic parameters in middle-aged men. J Atheroscler Thromb 2017;24:393–401CrossRef
31.
go back to reference Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002;123:745–750CrossRef Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002;123:745–750CrossRef
Metadata
Title
Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke
Authors
Takahisa Mori
Kazuhiro Yoshioka
Yuhei Tanno
Publication date
01-02-2022
Publisher
Springer India
Published in
Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10253-z

Other articles of this Issue 1/2022

Hepatology International 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.